Loading...
XTAE
BIOV
Market cap9mUSD
Apr 08, Last price  
28.70ILS
1D
0.00%
1Q
-1.03%
Jan 2017
-99.99%
IPO
-100.00%
Name

Bio-View Ltd

Chart & Performance

D1W1MN
No data to show
P/E
9,703.00
P/S
106.89
EPS
0.00
Div Yield, %
—
Shrs. gr., 5y
58.23%
Rev. gr., 5y
6.58%
Revenues
35m
+19.29%
25,318,00026,169,00026,047,00023,026,00030,242,00034,534,00033,289,00027,760,00025,280,00035,790,00025,960,00030,513,00029,145,00034,767,000
Net income
383k
-34.75%
5,236,0006,576,0001,442,000-1,076,0002,108,0004,066,0004,437,000-1,252,000-1,854,0002,525,000884,0002,184,000587,000383,000
CFO
153k
-84.19%
3,276,0002,350,000-2,916,0003,277,0004,662,0003,727,00054,000-1,325,0002,496,000802,0003,247,000968,000153,000
Dividend
Mar 22, 20172 ILS/sh

Profile

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. Its products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that include an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation with advanced review and analysis tools; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 2000 and is headquartered in Rehovot, Israel.
URL
http://bioview.com
IPO date
Mar 07, 2006
Employees
34
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
34,767
19.29%
29,145
-4.48%
Cost of revenue
34,630
21,552
Unusual Expense (Income)
NOPBT
137
7,593
NOPBT Margin
0.39%
26.05%
Operating Taxes
414
288
Tax Rate
302.19%
3.79%
NOPAT
(277)
7,305
Net income
383
-34.75%
587
-73.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,679)
(256)
BB yield
3.64%
0.00%
Debt
Debt current
1,555
1,265
Long-term debt
5,457
6,851
Deferred revenue
620
Other long-term liabilities
790
364
Net debt
(10,102)
(11,321)
Cash flow
Cash from operating activities
153
968
CAPEX
(274)
(457)
Cash from investing activities
(1,673)
(567)
Cash from financing activities
(2,683)
(1,612)
FCF
(1,124)
7,050
Balance
Cash
17,114
19,437
Long term investments
Excess cash
15,376
17,980
Stockholders' equity
(23,206)
(23,841)
Invested Capital
54,807
56,932
ROIC
12.78%
ROCE
0.43%
22.95%
EV
Common stock shares outstanding
140,119
13,908
Price
0.33
-99.99%
3,697.00
13.09%
Market cap
46,099
-99.91%
51,417,251
12.54%
EV
35,997
51,405,930
EBITDA
1,955
9,088
EV/EBITDA
18.41
5,656.46
Interest
311
236
Interest/NOPBT
227.01%
3.11%